CTIM-18. DENDRITIC CELL VACCINATION IN CONJUNCTION WITH ADJUVANT TLR-3 AGONIST ADMINISTRATION ENHANCES PRO-INFLAMMATORY IMMUNE RESPONSES AND IS ASSOCIATED WITH EXTENDED SURVIVAL IN MALIGNANT GLIOMA PATIENTS
Chavez C, Everson R, Orpilla J, Lee A, Khattab S, Antonios J, Salazar A, Cloughesy T, Liau L, Sun L, Hugo W, Prins R. CTIM-18. DENDRITIC CELL VACCINATION IN CONJUNCTION WITH ADJUVANT TLR-3 AGONIST ADMINISTRATION ENHANCES PRO-INFLAMMATORY IMMUNE RESPONSES AND IS ASSOCIATED WITH EXTENDED SURVIVAL IN MALIGNANT GLIOMA PATIENTS. Neuro-Oncology 2020, 22: ii36-ii37. PMCID: PMC7650313, DOI: 10.1093/neuonc/noaa215.152.Peer-Reviewed Original ResearchPatient's peripheral blood mononuclear cellsMalignant glioma patientsToll-like receptorsImmune responsePoly ICLCDendritic cellsClinical trialsTumor lysate-pulsed DCGlioma patientsTLR-3Lysate-pulsed DCPeripheral blood mononuclear cellsPhase II clinical trialTLR-7 agonistDendritic cell vaccinesPro-inflammatory immune responseWHO grade IIITLR-3 agonistIncreased expression of pro-inflammatory genesMGMT methylation statusBlood mononuclear cellsII clinical trialsExpression of pro-inflammatory genesPro-inflammatory responseExpression of pro-inflammatory factors